ANI Pharmaceuticals' stock surged 8.08% in the pre-market trading session on Friday, following the company's impressive fourth-quarter 2024 earnings report that exceeded Wall Street's expectations.
The pharmaceutical company reported adjusted earnings per share of $1.63, significantly beating the analyst consensus estimate of $1.44. Moreover, ANI Pharmaceuticals' quarterly sales of $190.57 million surpassed the estimated $175.37 million, representing a 44.75% year-over-year increase.
The strong financial results, driven by robust sales growth and better-than-expected profitability, have fueled investor confidence in ANI Pharmaceuticals' prospects, leading to the pre-market stock rally.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。